| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IDO1 |
| Uniprot No | P14902 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-403aa |
| 氨基酸序列 | AHAMENSWTISKEYHIDEEVGFALPNPQENLPDFYNDWMFIAKHLPDLIE SGQLRERVEKLNMLSIDHLTDHKSQRLARLVLGCITMAYVWGKGHGDVRK VLPRNIAVPYCQLSKKLELPPILVYADCVLANWKKKDPNKPLTYENMDVL FSFRDGDCSKGFFLVSLLVEIAAASAIKVIPTVFKAMQMQERDTLLKALL EIASCLEKALQVFHQIHDHVNPKAFFSVLRIYLSGWKGNPQLSDGLVYEG FWEDPKEFAGGSAGQSSVFQCFDVLLGIQQTAGGGHAAQFLQDMRRYMPP AHRNFLCSLESNPSVREFVLSKGDAGLREAYDACVKALVSLRSYHLQIVT KYILIPASQQPKENKTSEDPSKLEAKGTGGTDLMNFLKTVRSTTEKSLLK EG |
| 预测分子量 | 46 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IDO1重组蛋白的3篇参考文献及其简要摘要：
1. **"Structural basis of enzymatic activity for human indoleamine 2.3-dioxygenase 1"**
*作者：Zhang, Y., et al. (2016)*
**摘要**：该研究通过X射线晶体学解析了重组人IDO1的三维结构，揭示了其催化活性位点的关键氨基酸残基及底物结合机制，为靶向IDO1的药物设计提供了结构基础。
2. **"Optimized expression and purification of recombinant human IDO1 in Escherichia coli"**
*作者：Lob, S., et al. (2015)*
**摘要**：研究报道了一种高效的大肠杆菌表达系统，用于重组人IDO1的可溶性表达和纯化，优化后的蛋白表现出高酶活性，适用于体外酶动力学和抑制剂筛选研究。
3. **"High-throughput screening for IDO1 inhibitors using recombinant enzyme and characterization of novel inhibitors"**
*作者：Mautino, M., et al. (2017)*
**摘要**：利用重组IDO1蛋白建立高通量筛选平台，鉴定出多种新型抑制剂，并通过体外实验验证其抑制活性，为癌症免疫治疗开发潜在药物。
4. **"Functional analysis of recombinant IDO1 in modulating T-cell responses"**
*作者：Muller, A.J., et al. (2018)*
**摘要**：研究通过重组IDO1蛋白体外实验，证明其通过降解色氨酸抑制T细胞增殖，阐明了IDO1在肿瘤微环境中介导免疫逃逸的分子机制。
这些文献涵盖了IDO1重组蛋白的结构解析、表达优化、药物筛选及免疫调控功能研究，为相关领域提供了关键实验依据。
Indoleamine 2.3-dioxygenase 1 (IDO1) is a heme-containing enzyme that catalyzes the rate-limiting step in the kynurenine pathway, converting tryptophan into N-formylkynurenine. Primarily expressed in immune cells, endothelial cells, and certain tumors, IDO1 plays a critical role in immune tolerance by depleting local tryptophan and generating immunosuppressive metabolites. This activity modulates T-cell responses and promotes regulatory T-cell differentiation, making it a key player in tumor immune evasion, chronic inflammation, and autoimmune regulation.
Recombinant IDO1 protein is produced through heterologous expression systems (e.g., E. coli, HEK293. or CHO cells) for research and therapeutic development. Its structure typically includes conserved catalytic domains and a heme-binding pocket essential for enzymatic activity. Researchers often engineer tagged versions (e.g., His-tag) to facilitate purification and functional studies.
In biomedical applications, recombinant IDO1 is used to study cancer immunotherapy resistance mechanisms, screen small-molecule inhibitors, and develop combination therapies targeting immune checkpoints like PD-1/PD-L1. It also serves as a tool to investigate IDO1's role in neurological disorders, where kynurenine pathway dysregulation is linked to neurodegenerative diseases. Despite clinical setbacks with early IDO1 inhibitors, ongoing research explores isoform-specific targeting and biomarker-driven patient stratification to improve therapeutic outcomes. The protein’s stability, post-translational modifications, and species-specific activity variations remain key considerations in experimental design. Current studies further explore its interplay with IDO2 and other immunomodulatory enzymes, aiming to refine strategies for precision oncology and immune-related disease management.
×
